Choose Your Country or Region

Gadodiamide Hydrate

Catalog No.S1751 Purity: 99.08%

Gadodiamide Hydrate, a nonionic Gd3+ chelate, is frequently injected i.v. into magnetic resonance imaging (MRI) to enhance contrast.

Gadodiamide Hydrate Chemical Structure

CAS: 122795-43-1

Selleck's Gadodiamide Hydrate has been cited by 5 Publications

1 Customer Review

Purity & Quality Control

Batch: Purity: 99.08%

99.08

Gadodiamide Hydrate Related Products

Related Compound Libraries	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Bioactive Compound Library-Ⅱ Express-Pick Library	Click to Expand

Biological Activity

Description	Gadodiamide Hydrate, a nonionic Gd3+ chelate, is frequently injected i.v. into magnetic resonance imaging (MRI) to enhance contrast.

In Vivo
In vivo	Gadodiamide results in half-life of 18, 38, and 75 minutes in rats, rabbits, and monkeys, respectively. Gadodiamide is shown to be excreted rapidly, primarily through the kidneys. ^[1] Gadodiamide, when administered i.v. as gadodiamide injection at a dosage of 0.3 mmol/kg, is stable in vivo and that the very major part of the dose (> 99%) is excreted in urine as an unchanged complex. ^[2] Gadodiamide produces focal and generalized myoclonus over several hours. Gadodiamide itself produces lesions in the central cerebellar regions resembling in character and severity those produced by the gadodiamide formulation, but not others. ^[3] Gadodiamide travels quickly throughout the ventricular system from the lateral ventricular site of injection to the fourth ventricle and foramina of Luschka and Magendie within 2 min. ^[4] Gadodiamide results in transient but statistically significant decreases in aortic pressure, left ventricular pressure, indices of left ventricular contractility and relaxation, and systemic and pulmonary vascular resistance, and increases in aortic blood flow in anesthetized dogs. Gadodiamide injection produces less severe alterations in hemodynamics than gadopentetate dimeglumine. ^[5]

References
[1] Harpur ES, et al. Invest Radiol, 1993, 28, S28-43. [2] Normann PT, et al. Eur J Drug Metab Pharmacokinet, 1995, 20(4), 307-313. [3] Ray DE, et al. AJNR Am J Neuroradiol, 1998, 19(8), 1455-1462. [4] Bui JD, et al. Neuroscience, 1999, 90(3), 1115-1122. [5] Peters JL, et al. Acta Radiol, 1993, 34(5), 510-516. + Expand

References

+ Expand

Chemical Information & Solubility

Molecular Weight	591.67	Formula	C₁₆H₂₈GdN₅O₉C₁₆H₂₈GdN₅O₉.xH₂O
CAS No.	122795-43-1	SDF	Download Gadodiamide Hydrate SDF
Smiles	CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3]
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):